[Corrections] Corrections

Ballard C, Banister C, Khan Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol 2018; 17: 213 –22—In the online Appendix on page 5, a figure has been added showing the adjusted mean change from baseline to week 12 for NPI–NH psychosis score of 12 or more and the figure legend should read “Adjusted mean (SE) change from baseline in NPI-NH psychosis score for patients with baseline sco re ≥12.” Additionally on page 6 in the Appendix, a figure has been added showing the adjusted mean change from baseline to week 12 for NPI–NH psychosis score of less than 12 and a figure legend has been added, which should read “Adjusted mean (SE) change from baseline in NPI-NH psychosis sco re for patients with baseline score
Source: Lancet Neurology - Category: Neurology Tags: Corrections Source Type: research